Search Browse Earnings

Cogent Biosciences, Inc. — SlamSEC

Cogent Biosciences, Inc.

Nasdaq:COGT

Pharmaceutical Preparations·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$7.9M

-65.0% YoY

FY 2021

Adj. EBITDA

-$205.8M

-2615.0% margin

FY 2025

Net Income

-$192.4M

-2444.5% margin

FY 2025

EPS (Diluted)

-$1.94

FY 2025

Stock Price

$34.00

-3.8%

2026-03-13

52W Range

$3.72 – $43.73

P/E Ratio

-17.5x

Market Cap

$5.5B

Cash

$98.2M

FY 2025

Total Debt

$222.9M

FY 2025

Net Debt

$124.7M

FY 2025

Enterprise Value

$5.6B

Debt / EBITDA

-0.6x

FY 2021

EV / EBITDA

-27.4x

Employees

—